KLRK1 and prostate cancer: Human prostate cancer-derived EVs express ligands for NKG2D on their surface, which selectively decreases the expression of the receptor NKG2D on NK and CD8+ killer T cells in a dose-dependent manner, leading to impairing the cytotoxic function of these killer cells and promoting tumor immune escape [141].